Belimumab

Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), used in the treatment of active systemic lupus erythematosus (SLE) and lupus nephritis. It reduces the survival of B cells, decreasing autoantibody production. Mediocon Inc supplies pharmaceutical-grade Belimumab for biopharmaceutical manufacturers.

Key Features

• Anti-BLyS monoclonal antibody
• IP/BP/EP/USP compliant quality
• Systemic lupus erythematosus treatment
• IV and subcutaneous formulations available

Applications

• SLE IV infusion formulations
• Subcutaneous auto-injector
• Lupus nephritis treatment
• Biopharmaceutical manufacturing

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings